drugset

drugset / Trial / NCT00640146

Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures

NCT00640146 ↗

Phase 2 Completed 37 enrolled Bausch Health Americas, Inc. Wyeth is now a wholly owned subsidiary of Pfizer · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to examine the safety and activity of MNTX in relieving opioid-induced constipation following orthopedic procedures.

Timeline

Start: 2007-10-19
Primary completion: 2009-01-21
Completion: 2009-01-21

Publications

Anissian L, Schwartz HW, Vincent K, Vincent HK, Carpenito J, Stambler N, Ramakrishna T. Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: phase 2 study in rehabilitation after orthopedic surgery. J Hosp Med. 2012 Feb;7(2):67-72. doi: 10.1002/jhm.943. Epub 2011 Oct 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Methylnaltrexone	Other / unclassified	12 mg	Subcutaneous

Indications